[Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Acute myeloid leukemia (AML) is a genetically heterogeneous disease. The genetic diagnostics have  become an essential component in the initial work-up for disease classification, prognostication and prediction. More and more promising molecular targeted therapeutics are becoming available. A prerequisite for individualized treatment strategies is a fast pretherapeutic molecular screening including the fusion genes PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 as well as mutations in the genes NPM1, FLT3 and CEBPA. Promising new therapeutic approaches include the combination of all-                 trans retinoic acid and arsentrioxid in acute promyelocytic leukemia, the combination of intensive chemotherapy with KIT inhibitors in core-binding factor AML and FLT3 inhibitors in AML with FLT3 mutation, as well as gemtuzumab ozogamicin therapy in patients with low and intermediate cytogenetic risk profiles. With the advent of the next generation sequencing technologies it is expected that new therapeutic targets will be identified. These insights will lead to a further individualization of AML therapy.
Klinik für Innere Medizin III, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm.
R F
RF
Schlenk
K
K
Döhner
H
H
Döhner
D015415:Biomarkers / Q000032:analysis; D005819:Genetic Markers / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D058990:Molecular Targeted Therapy / Q000639:trends*; D000090243:Nucleophosmin; D057285:Precision Medicine / Q000379:methods*
D015415:Biomarkers; D005819:Genetic Markers; C000716967:NPM1 protein, human; D000090243:Nucleophosmin